Futura Medical (FUM) RNS Announcements

Add to Alert list
Date Time Source Announcement
29 Apr 2024 07:00 AM
RNS
Directors’ / PDMR Dealing and Grant of Options
10 Apr 2024 07:00 AM
RNS
Results for the Year ended 31 December 2023
25 Mar 2024 07:00 AM
RNS
Notice of Results and Investor Presentation
14 Feb 2024 07:00 AM
RNS
Eroxon to be available on prescription
06 Feb 2024 07:01 AM
RNS
Trading Update
06 Feb 2024 07:00 AM
RNS
Appointment of Joint Corporate Broker
17 Jan 2024 07:00 AM
RNS
Director/PDMR Dealing
17 Jan 2024 07:00 AM
RNS
Remuneration of Non-Exec Directors & Voting Rights
15 Jan 2024 07:00 AM
RNS
Futura Medical extends collaboration with Cooper
09 Jan 2024 07:00 AM
RNS
Appointment of Roy Davis as Non-Executive Director
30 Nov 2023 03:10 PM
RNS
Total Voting Rights
30 Nov 2023 03:10 PM
RNS
Block Listing Six Monthly Return
07 Nov 2023 07:00 AM
RNS
Futura expands partnership with M8 Pharmaceuticals
02 Nov 2023 03:34 PM
RNS
Eroxon Awarded “New Product of the Year” by Boots
31 Oct 2023 07:00 AM
RNS
Block Listing Application and Total Voting Rights
25 Oct 2023 07:00 AM
RNS
Eroxon® Granted Marketing Authorisation in Mexico
19 Oct 2023 07:00 AM
RNS
Eroxon Launches in the United Arab Emirates
10 Oct 2023 07:00 AM
RNS
Directors’/PDMR Dealing and Grant of Options
02 Oct 2023 07:00 AM
RNS
European Patent Granted for MED3000 until 2040
18 Sep 2023 07:00 AM
RNS
Futura Medical - Interim Results 2023
18 Aug 2023 07:00 AM
RNS
Futura Medical - Notice of Interim Results
09 Aug 2023 07:00 AM
RNS
MED3000 Commercialisation Approval in Saudi Arabia
31 Jul 2023 07:00 AM
RNS
Futura Medical - Total Voting Rights
18 Jul 2023 11:04 AM
RNS
Board Change
17 Jul 2023 07:00 AM
RNS
Futura/Haleon Enter US Commercialisation Agreement
30 Jun 2023 07:00 AM
RNS
Futura Medical - Total Voting Rights
23 Jun 2023 04:30 PM
RNS
Recording of Investor Seminar
22 Jun 2023 03:19 PM
RNS
Futura Medical Annual General Meeting Results
22 Jun 2023 07:00 AM
RNS
Futura Medical AGM Statement
19 Jun 2023 10:25 AM
RNS
Correction - TR-1: Notification of major holdings
16 Jun 2023 04:05 PM
RNS
TR-1: Notification of major holdings
12 Jun 2023 08:23 AM
RNS
Exercise of Warrants
12 Jun 2023 07:00 AM
RNS
MED3000 Granted US FDA Approval for OTC Sale
08 Jun 2023 07:00 AM
RNS
Futura Medical Announces Investor Seminar
31 May 2023 07:00 AM
RNS
Block Listing Six Monthly Return
26 May 2023 07:00 AM
RNS
Notice of AGM and availability of Annual Report
24 Apr 2023 07:00 AM
RNS
TR-1: Notification of major holdings
24 Apr 2023 07:00 AM
RNS
TR-1: Notification of major holdings
18 Apr 2023 07:00 AM
RNS
MED3000, Eroxon® UK Launch
06 Apr 2023 11:03 AM
RNS
Directors' / PDMR Dealing and Grant of Options
05 Apr 2023 07:00 AM
RNS
Full Year Results ended 31 December 2022
29 Mar 2023 07:00 AM
RNS
Update on MED3000 regulatory approval in the US
27 Mar 2023 05:24 PM
RNS
Notice of Preliminary Results 2022
14 Mar 2023 08:33 AM
RNS
MED3000 commercial and US regulatory update
15 Feb 2023 07:00 AM
RNS
MED3000 FM71 Presentation at ESSM Congress 2023
01 Feb 2023 01:26 PM
RNS
Block Listing Applications to AIM
26 Jan 2023 07:00 AM
RNS
Pre-launch of MED3000 ahead of H1 2023 launch
12 Jan 2023 11:09 AM
RNS
Futura Remuneration, Options & Total Voting Rights
15 Dec 2022 03:01 PM
RNS
TR-1: Notification of major holdings
13 Dec 2022 01:08 PM
EQS
Futura Medical 'on track' for launch in H1 2023

Futura Medical is the developer of innovative sexual health products, including lead product Eroxon®. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

It listed on AIM in 2003 under the ticker FUM.

UK 100

Latest directors dealings